Dipna Pharmachem PE ratio history and valuation
BSE: 543594Pharmaceuticals & BiotechnologySmall Cap
DIPNA PHARMACHEM LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2022
Last close ₹3.93up ₹0.20 (5.36%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹3.73.
30 Oct: open ₹3.86, high ₹3.93, low ₹3.82
52-week range of traded prices to 30 Oct 2026
₹3.62Low, 29 Oct 2026₹20.50High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹10 Cr3,953rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 24,000
Dipna Pharmachem's dividend yield on 30 Oct 2026, each against its own history of up to 5 years. It has no P/E yet: twelve months of its results are not on record.
Dipna Pharmachem PE ratio and valuation against its own history
- Price to earningsNo results for a period ending in the last six months, or nine for a company filing half-yearly
- Price to bookNo results for a period ending in the last six months, or nine for a company filing half-yearly
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.No results for a period ending in the last six months, or nine for a company filing half-yearly
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.No results for a period ending in the last six months, or nine for a company filing half-yearly
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
1 year
Median 0.00%Today is at or above 100% of the 227 days
3 years
Median 0.00%Today is at or above 100% of the 719 days
5 years, since Oct 2022
Median 0.00%Today is at or above 100% of the 964 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.No results for a period ending in the last six months, or nine for a company filing half-yearly
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.2,62,89,250at 30 Sep 2026
₹ crore.Dipna Pharmachem financials ›
Dipna Pharmachem valuation at each year end
On the last trading day of each March, the month the company's year ends.
| Ratio | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 15.0 | 11.3 | 34.4 | 21.1 |
| Price to earnings | No full year | 9.6 | 41.3 | 10.3 |
| Price to book | 0.6 | 0.5 | 0.9 | Shares changed |
| Price to sales | No full year | 0.1 | 0.2 | 0.2 |
| EV to EBITDA | No full year | Operating profit not stated | Operating profit not stated | Operating profit not stated |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings yield | No full year | 10.4% | 2.4% | 9.7% |
A ratio that does not exist on the day says why in its cell.
Dipna Pharmachem market cap, since Oct 2022
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Dividends and the public's market cap
From the close on 30 Oct 2026.
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹9.39 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Dipna Pharmachem is 210th among them by market cap. Each median leaves out Dipna Pharmachem itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 27.6Across 158 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 2.9Across 191 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.1Across 145 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.49%Across 90 other companies
| Company | |||||
|---|---|---|---|---|---|
 Desh Rakshak AushdhalayaDESHRAK | 15 | 27.77 | 1.15 | 13.0 | 0.00% |
 Beryl DrugsBERLDRG | 13 | 20.79 | 1.31 | 8.4 | 0.00% |
 Unjha FormulationsUNJHAFOR | 13 | 27.03 | 3.32 | 15.1 | 0.00% |
 Ortin GlobalORTINGLOBE | 11 | – | 8.77 | – | 0.00% |
| Dipna PharmachemDPL | 10 | – | – | – | 0.00% |
 Brawn BiotechBRAWN | 7 | 8.60 | 1.70 | – | 0.00% |
 Vivanza BiosciencesVIVANZA | 6 | 13.57 | 1.41 | 32.3 | 0.00% |
 Decipher LabsDECIPHER | 5 | – | 0.63 | – | 0.00% |
 Advik LaboratoriesADVIKLA | 4 | – | 58.03 | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.